dantrolene has been researched along with Subarachnoid Hemorrhage in 12 studies
Dantrolene: Skeletal muscle relaxant that acts by interfering with excitation-contraction coupling in the muscle fiber. It is used in spasticity and other neuromuscular abnormalities. Although the mechanism of action is probably not central, dantrolene is usually grouped with the central muscle relaxants.
dantrolene : The hydrazone resulting from the formal condensation of 5-(4-nitrophenyl)furfural with 1-aminohydantoin. A ryanodine receptor antagonist used for the relief of chronic severe spasticity and malignant hyperthermia.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this pilot study, a single dose of intravenous dantrolene in cerebral vasospasm after subarachnoid hemorrhage appears feasible while inhibiting vasoconstriction in the low-dose group, but it may lower blood pressure." | 9.15 | Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. ( Muehlschlegel, S; Rordorf, G; Sims, J, 2011) |
| "Dantrolene is a promising new therapeutic agent in the treatment of cerebral vasospasm." | 6.82 | The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. ( Nunna, RS; Ortiz, M; Qureshi, AI; Ravipati, K; Siddiq, F; Tran, A, 2022) |
| "Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm." | 5.51 | Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Jahngir, M; Litofsky, NS; Nattanmai, P; Ortiz Torres, MJ; Qualls, K; Qureshi, AI, 2019) |
| "We report a case of refractory cerebral vasospasm treated with intra-arterial dantrolene after aneurysmal subarachnoid hemorrhage." | 5.38 | Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Grigoryan, M; Majidi, S; Qureshi, AI; Tekle, WG, 2012) |
| "In this pilot study, a single dose of intravenous dantrolene in cerebral vasospasm after subarachnoid hemorrhage appears feasible while inhibiting vasoconstriction in the low-dose group, but it may lower blood pressure." | 5.15 | Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study. ( Muehlschlegel, S; Rordorf, G; Sims, J, 2011) |
| "In New Zealand white rabbits (N = 22), vasospasm was individually provoked through experimentally induced subarachnoid hemorrhage and confirmed via conventional angiography, grouping animals by IA-infused drug (nicardipine vs." | 4.12 | Comparative Study of Vasodilatation After Intra-arterial Nicardipine or Dantrolene Infusion in Animal Model of Cerebral Vasospasm. ( Byoun, HS; Cho, YD; Lim, J, 2022) |
| "Dantrolene is a promising new therapeutic agent in the treatment of cerebral vasospasm." | 2.82 | The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review. ( Nunna, RS; Ortiz, M; Qureshi, AI; Ravipati, K; Siddiq, F; Tran, A, 2022) |
| " Three patients in the IV-D versus two in the placebo group had severe adverse events possibly attributable to infusion and reached stop criteria: one IV-D patient developed liver toxicity; two patients in each group developed brain oedema requiring osmotherapy." | 2.80 | Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial. ( Barton, B; Carandang, R; Flood, TF; Garland, B; Gounis, MJ; Hall, W; Izzy, S; Kini, N; Muehlschlegel, S; Ouillette, C; van der Bom, IM; Wakhloo, AK; Weaver, JP, 2015) |
| " Dose-response curves for the 5-HT-induced contraction (from 0." | 1.62 | The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats. ( Crespo, MJ; García, L; Morales, M; Román, M, 2021) |
| "Dantrolene has a safe side-effect profile and a mechanism of action that makes it attractive as an option for treatment of cerebral vasospasm." | 1.51 | Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage. ( Jahngir, M; Litofsky, NS; Nattanmai, P; Ortiz Torres, MJ; Qualls, K; Qureshi, AI, 2019) |
| "We report a case of refractory cerebral vasospasm treated with intra-arterial dantrolene after aneurysmal subarachnoid hemorrhage." | 1.38 | Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. ( Grigoryan, M; Majidi, S; Qureshi, AI; Tekle, WG, 2012) |
| "According to the diagnostic criteria for malignant hyperthermia by Larach and his colleague, malignant hyperthermia was somewhat less than likely in our case." | 1.33 | [Central hyperthermia suspected of malignant hyperthermia in a patient undergoing radical neck clipping for cerebral aneurysm]. ( Matsuki, A; Murakawa, T; Sakai, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 6 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ortiz, M | 2 |
| Nunna, RS | 1 |
| Ravipati, K | 1 |
| Tran, A | 1 |
| Qureshi, AI | 3 |
| Siddiq, F | 1 |
| Lim, J | 1 |
| Cho, YD | 1 |
| Byoun, HS | 1 |
| Crespo, MJ | 2 |
| Román, M | 2 |
| Tirado, G | 1 |
| Martins, AH | 1 |
| Ferrer-Acosta, Y | 1 |
| Martinez-Jimenez, SM | 1 |
| Bongetta, D | 1 |
| De Pirro, A | 1 |
| Iotti, GA | 1 |
| Assietti, R | 1 |
| Jahngir, M | 2 |
| Qualls, K | 2 |
| Litofsky, NS | 2 |
| Nattanmai, P | 2 |
| Qureshi, A | 1 |
| García, L | 1 |
| Morales, M | 1 |
| Ortiz Torres, MJ | 1 |
| Muehlschlegel, S | 3 |
| Carandang, R | 1 |
| Hall, W | 1 |
| Kini, N | 1 |
| Izzy, S | 1 |
| Garland, B | 1 |
| Ouillette, C | 1 |
| van der Bom, IM | 1 |
| Flood, TF | 1 |
| Gounis, MJ | 1 |
| Weaver, JP | 1 |
| Barton, B | 1 |
| Wakhloo, AK | 1 |
| Rordorf, G | 2 |
| Bodock, M | 1 |
| Sims, JR | 1 |
| Sims, J | 1 |
| Majidi, S | 1 |
| Grigoryan, M | 1 |
| Tekle, WG | 1 |
| Murakawa, T | 1 |
| Sakai, I | 1 |
| Matsuki, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dantrolene in the Prevention and Treatment of Cerebral Vasospasm in Subarachnoid Hemorrhage[NCT01024972] | Phase 1/Phase 2 | 31 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Dantrolene in the Treatment of Cerebral Vasospasm After Subarachnoid Hemorrhage - a Phase 1 Study[NCT00964548] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of subjects who developed hyponatremia (sNa ≤132mmol/L) (NCT01024972)
Timeframe: Seven days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 7 |
| Placebo | 10 |
Number of subjects who expired during hospitalization. (NCT01024972)
Timeframe: up to 90 days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 2 |
| Placebo | 1 |
Number of subjects who developed liver toxicity as evidenced by Liver Function Test elevation greater than 5 times the upper limit of normal. (NCT01024972)
Timeframe: 7 days
| Intervention | participants (Number) |
|---|---|
| Dantrolene | 1 |
| Placebo | 0 |
Systolic Blood Pressure (Change from baseline systolic blood pressure (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | mmHg (Mean) |
|---|---|
| Dantrolene (Low Dose) | -8 |
| Dantrolene (High Dose) | -3.4 |
Mean flow velocities of vessel in vasospasm (Change from baseline mean flow velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | cm/s (Mean) |
|---|---|
| Dantrolene (Low Dose) | -18 |
| Dantrolene (High Dose) | -13 |
Peak Systolic Velocity of vessel in vasospasm (Change from baseline peak systolic velocity (pre-infusion) over time until 135 minutes post-infusion). (NCT00964548)
Timeframe: baseline until 135 minutes post-infusion
| Intervention | cm/s (Mean) |
|---|---|
| Dantrolene (Low Dose) | -30 |
| Dantrolene (High Dose) | -26 |
1 review available for dantrolene and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
The Role of Parenteral Dantrolene in the Contemporary Management of Cerebral Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review.
Topics: Animals; Dantrolene; Humans; Prospective Studies; Retrospective Studies; Subarachnoid Hemorrhage; Va | 2022 |
2 trials available for dantrolene and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial.
Topics: Adult; Aged; Dantrolene; Double-Blind Method; Female; Humans; Male; Middle Aged; Muscle Relaxants, C | 2015 |
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu | 2011 |
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu | 2011 |
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu | 2011 |
Effects of a single dose of dantrolene in patients with cerebral vasospasm after subarachnoid hemorrhage: a prospective pilot study.
Topics: Adult; Blood Pressure; Dantrolene; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hu | 2011 |
9 other studies available for dantrolene and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Comparative Study of Vasodilatation After Intra-arterial Nicardipine or Dantrolene Infusion in Animal Model of Cerebral Vasospasm.
Topics: Animals; Dantrolene; Models, Animal; Nicardipine; Rabbits; Subarachnoid Hemorrhage; Vasospasm, Intra | 2022 |
Dantrolene Significantly Improves Cerebral Blood Flow in a Rat Model of Hemorrhagic Vasospasms.
Topics: Animals; Cerebrovascular Circulation; Dantrolene; Nimodipine; Rats; Rats, Sprague-Dawley; Subarachno | 2023 |
Letter to the Editor Regarding "Intraarterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage": Is Malignant Hyperthermia a Model for Showing Dantrolene Efficacy in Limiting Brain Damage?
Topics: Brain; Dantrolene; Humans; Malignant Hyperthermia; Subarachnoid Hemorrhage; Vasospasm, Intracranial | 2020 |
In Reply to the Letter to the Editor Regarding "Intra-arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage".
Topics: Cerebral Angiography; Dantrolene; Humans; Infusions, Intra-Arterial; Subarachnoid Hemorrhage; Vasosp | 2020 |
The combination of dantrolene and nimodipine effectively reduces 5-HT-induced vasospasms in diabetic rats.
Topics: Animals; Calcium Channel Blockers; Dantrolene; Diabetes Mellitus, Experimental; Drug Therapy, Combin | 2021 |
Intra-Arterial Dantrolene for Refractory Cerebral Vasospasm in Patients with Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Dantrolene; Female; Humans; Infusions, Intra-Arterial; Middle Aged; Muscle Relaxants, Central | 2019 |
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent | 2009 |
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent | 2009 |
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent | 2009 |
Dantrolene mediates vasorelaxation in cerebral vasoconstriction: a case series.
Topics: Adult; Dantrolene; Female; Humans; Male; Middle Aged; Middle Cerebral Artery; Muscle Relaxants, Cent | 2009 |
Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Topics: Angioplasty, Balloon; Anterior Cerebral Artery; Cerebral Angiography; Dantrolene; Female; Humans; In | 2012 |
[Central hyperthermia suspected of malignant hyperthermia in a patient undergoing radical neck clipping for cerebral aneurysm].
Topics: Anesthesia, General; Creatine Kinase; Dantrolene; Diagnosis, Differential; Female; Fever; Humans; Hy | 2005 |